SCM
GPCR icon

Sterling Capital Management’s Structure Therapeutics GPCR Stock Holding History

Sterling Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
2,045
+1,455
+247% +$64.4K ﹤0.01% 1374
2026
Q1 		$28.4K Buy
+590
New +$40.4K ﹤0.01% 1860

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sterling Capital Management's GPCR Position: Q2 2026 in Review

Sterling Capital Management increased its Structure Therapeutics (GPCR) stake by 247% in Q2 2026, buying an estimated $64.4K and bringing the position to 2,045 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Sterling Capital Management first reported a position in GPCR in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Sterling Capital Management held 2,045 shares of Structure Therapeutics worth $110K as of Q2 2026.
  • Sterling Capital Management bought 1,455 Structure Therapeutics shares in Q2 2026, an estimated $64.4K.
  • Structure Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1374 holding.
  • Sterling Capital Management first reported a position in Structure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.